In Brief: Pfizer OTC, Moberg, Atrium, C&D, Wockhardt, Herbalife
This article was originally published in The Tan Sheet
Executive Summary
Pfizer expands European OTC business; Moberg expands in U.S. with Bayer brands; Atrium would go private in $1.1 billion deal; C&D not bearish on gummies; GMP warning for two Wockhardt facilities; and Belgian court: Herbalife not a pyramid scheme.
You may also be interested in...
Herbalife Pushes To Counter Pyramid Scheme Narrative
The multilevel marketer of weight-management shakes and other nutritionals says its independent distributor network, far from being a pyramid scheme, in fact is essential in helping people lose weight and adopt healthy lifestyles, according to Herbalife executives.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.